Clinical data of the individuals investigated
| Subject . | HLA . | Start of therapy . | Time to AIDS . | AIDS diagnosis . | Dominant response* . |
|---|---|---|---|---|---|
| 1081 | A2,3; B37,62; CW3,6 | — | 101 | Wasting syndrome | SLY |
| 57 | A2,19; B27,40; CW2 | — | — | — | SLY |
| 16 | A2,29; B44,51; CW2,5 | — | 131 | Kaposi sarcoma | SLY + ILK |
| 490 | A2,23; B44,51; CW2,4 | 120† | 128 | Cryptococcus | SLY |
| 1211 | A2,29; B44; CW4 | — | 68 | Crypt meningitis | SLY |
| 1140 | A2,11; B40,52; CW3 | 119‡ | —1-153 | — | SLY |
| 434 | A2,28; B7,27; CW2 | 134‡ | —1-153 | — | SLY |
| 433 | A2,3; B7,57; CW6,7 | — | 84 | CMV | KAF |
| 658 | A1,2; B8,61; CW2,7 | — | — | — | EIY + FLK |
| 1160 | A2; B8,27; CW1 | — | — | — | EIY + FLK |
| 341 | A24,28; B8,13, CW6,7 | 901-155 | 115 | CD4 < 200 | FLK |
| 232 | A1,3; B7,8; CW7 | 82,1-155123‡ | 127 | Tuberculosis | EIY + FLK |
| 656 | A1,11; B8,56; CW1 | 49† | 78 | Cryptosporidiasis | FLK |
| 748 | A1; B8; CW7 | 33† | 47 | CD4 < 200 | EIY + FLK |
| 424 | A1,2; B8,61; CW2,7 | — | 41 | Candidiasis | FLK |
| 159 | A1; B8; CW7 | 33† | 33 | Pneumocystis carinii | EIY |
| Subject . | HLA . | Start of therapy . | Time to AIDS . | AIDS diagnosis . | Dominant response* . |
|---|---|---|---|---|---|
| 1081 | A2,3; B37,62; CW3,6 | — | 101 | Wasting syndrome | SLY |
| 57 | A2,19; B27,40; CW2 | — | — | — | SLY |
| 16 | A2,29; B44,51; CW2,5 | — | 131 | Kaposi sarcoma | SLY + ILK |
| 490 | A2,23; B44,51; CW2,4 | 120† | 128 | Cryptococcus | SLY |
| 1211 | A2,29; B44; CW4 | — | 68 | Crypt meningitis | SLY |
| 1140 | A2,11; B40,52; CW3 | 119‡ | —1-153 | — | SLY |
| 434 | A2,28; B7,27; CW2 | 134‡ | —1-153 | — | SLY |
| 433 | A2,3; B7,57; CW6,7 | — | 84 | CMV | KAF |
| 658 | A1,2; B8,61; CW2,7 | — | — | — | EIY + FLK |
| 1160 | A2; B8,27; CW1 | — | — | — | EIY + FLK |
| 341 | A24,28; B8,13, CW6,7 | 901-155 | 115 | CD4 < 200 | FLK |
| 232 | A1,3; B7,8; CW7 | 82,1-155123‡ | 127 | Tuberculosis | EIY + FLK |
| 656 | A1,11; B8,56; CW1 | 49† | 78 | Cryptosporidiasis | FLK |
| 748 | A1; B8; CW7 | 33† | 47 | CD4 < 200 | EIY + FLK |
| 424 | A1,2; B8,61; CW2,7 | — | 41 | Candidiasis | FLK |
| 159 | A1; B8; CW7 | 33† | 33 | Pneumocystis carinii | EIY |
Crypt indicates cryptococcus; CMV, cytomegalovirus.
Peptides listed in materials section are indicated with the first 3 amino acids.
Months after seroconversion at which zidovudine (AZT) treatment is initiated.
Months after seroconversion at which HAART is initiated.
Subjects 1140 and 434 did not develop AIDS but started HAART because of high viral load and decreasing CD4 T cell numbers.
Months after seroconversion at which AZT plus dideoxyinosine (DDI) treatment is initiated.